CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and cd4+ T effector cells in patients with head and neck squamous cell carcinoma

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 659-669

  Mandapathil, Magis ^a,b   Szczepanski, Miroslaw J ^a   Harasymczuk, Malgorzata ^a   Ren, Jin ^c   Cheng, Dongmei ^c   Jackson, Edwin K ^c   Gorelik, Elieser ^a,c   Johnson, Jonas T ^a,c   Lang, Stephan ^b   Whiteside, Theresa L ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine; Adenosine deaminase (ADA); Cancer; Teff; Treg

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE RECEPTOR; CADO PROTEIN; CELL ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; CD4+ CD39+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EFFECTOR CELL; ENZYME ACTIVITY; EXTRACELLULAR SPACE; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION;

EID: 84875670622     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20387     Document Type: Article

References (43)

1. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010; 22:223-30; PMID:20207527; http://dx.doi. org/10.1016/j.coi.2010.02.005.
2. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010; 125:195-203; PMID:20042227; http://dx.doi. org/10.1016/j.jaci.2009.08.040.
3. Schetinger MR, Morsch VM, Bonan CD, Wyse AT. NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. Biofactors 2007; 31:77-98; PMID:18806312; http://dx.doi.org/10.1002/biof.5520310205.
4. + regulatory T cells. J Biol Chem 2010; 285:7176-86; PMID:19858205; http://dx.doi.org/10.1074/jbc.M109.047423.
5. + T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res 2007; 67:5949-56; PMID:17575165; http://dx.doi. org/10.1158/0008-5472.CAN-06-4249.
6. Lokshin A, Raskovalova T, Huang X, Zacharia LC, Jackson EK, Gorelik E. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res 2006; 66:7758-65; PMID:16885379; http://dx.doi. org/10.1158/0008-5472.CAN-06-0478.
7. Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996; 156:1349-55; PMID:8568233.
8. Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS. The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J Exp Med 2000; 192:1223-36; PMID:11067872; http://dx.doi. org/10.1084/jem.192.9.1223.
9. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998; 161:55-70; PMID:9553764; http://dx.doi. org/10.1111/j.1600-065X.1998.tb01571.x.
10. Hirschhorn R. Adenosine deaminase deficiency. Immunodefic Rev 1990; 2:175-98; PMID:2078332.
11. Hershfield MS. New insights into adenosine-receptor- mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005; 35:25-30; PMID:15580654; http://dx.doi. org/10.1002/eji.200425738.
12. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002; 14:99-108; PMID:11781133; http://dx.doi.org/10.1016/S0898-6568(01)00235-2.
13. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414:916-20; PMID:11780065; http://dx.doi. org/10.1038/414916a.
14. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005; 175:4383-91; PMID:16177079.
15. Sitkovsky MV, Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 2005; 26:299-304; PMID:15922945; http://dx.doi.org/10.1016/j.it.2005.04.004.
16. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-32; PMID:17449799; http://dx.doi. org/10.1182/blood-2006-12-064527.
17. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65; PMID:17502665; http://dx.doi.org/10.1084/ jem.20062512.
18. Mandapathil M, Szczepanski MJ, Szajnik M, Ren J, Lenzner DE, Jackson EK, et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009; 15:6348-57; PMID:19825957; http://dx.doi. org/10.1158/1078-0432.CCR-09-1143.
19. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303-10; PMID:11390437; http://dx.doi.org/10.1084/ jem.193.11.1303.
20. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182:68-79; PMID:11722624; http://dx.doi. org/10.1034/j.1600-065X.2001.1820105.x.
21. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol 2009; 16:274-9; PMID:19417650; http://dx.doi.org/10.1097/ MOH.0b013e32832a9a01.
22. Beyer M, Schultze JL. Immunoregulatory T cells: role and potential as a target in malignancy. Curr Oncol Rep 2008; 10:130-6; PMID:18377826; http://dx.doi. org/10.1007/s11912-008-0021-z.
23. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27:5904-12; PMID:18836471; http://dx.doi. org/10.1038/onc.2008.271.
24. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008; 14:5947-52; PMID:18829471; http://dx.doi.org/10.1158/1078-0432.CCR-08-0229.
25. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29:5346-58; PMID:20661219; http://dx.doi.org/10.1038/ onc.2010.292.
26. + T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol 2008; 29:99-102; PMID:18258482; http://dx.doi.org/10.1016/j. it.2007.12.005.
27. Komi Y, Ohno O, Suzuki Y, Shimamura M, Shimokado K, Umezawa K, et al. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin. Jpn J Clin Oncol 2007; 37:867-73; PMID:17956898; http://dx.doi.org/10.1093/jjco/ hym115.
28. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. Int J Oncol 2008; 32:527-35; PMID:18292929.
29. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009; 346:55-63; PMID:19450601; http://dx.doi.org/10.1016/j. jim.2009.05.004.
30. + T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011; 369:59-68; PMID:21513715; http://dx.doi. org/10.1016/j.jim.2011.04.004.
31. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007; 5:62; PMID:18047662; http://dx.doi. org/10.1186/1479-5876-5-62.
32. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14:3706-15; PMID:18559587; http://dx.doi.org/10.1158/1078-0432.CCR-07-5126.
33. Climent N, Martinez-Navio JM, Gil C, Garcia F, Rovira C, Hurtado C, et al. Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. Immunol Cell Biol 2009; 87:634-9; PMID:19668260; http://dx.doi. org/10.1038/icb.2009.53.
34. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008; 38:925-7; PMID:18395862; http://dx.doi. org/10.1002/eji.200838168.
35. Ehrentraut H, Westrich JA, Eltzschig HK, Clambey ET. Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation. PLoS One 2012; 7:12; PMID:22389701; http://dx.doi.org/10.1371/journal. pone.0032416.
36. Cordero OJ, Salgado FJ, Fernández-Alonso CM, Herrera C, Lluis C, Franco R, et al. Cytokines regulate membrane adenosine deaminase on human activated lymphocytes. J Leukoc Biol 2001; 70:920-30; PMID:11739555.
37. Linden J. Adenosine metabolism and cancer. Focus on "Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatases and reducing ERK1/2 activity via a novel pathway". Am J Physiol Cell Physiol 2006; 291:405-6; PMID:16707553; http://dx.doi.org/10.1152/ajpcell. 00242.2006.
38. Eric-Nikolic A, Matic IZ, Dordevic M, Milovanovic Z, Markovic I, Dẑodic R, et al. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology 2011; 216:942-6; PMID:21281985; http://dx.doi. org/10.1016/j.imbio.2011.01.005.
39. Van Linden A, Eltzschig HK. Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin Biol Ther 2007; 7:1437-47; PMID:17727332; http://dx.doi. org/10.1517/14712598.7.9.1437.
40. Salamone JD. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. IDrugs 2010; 13:723-31; PMID:20878595.
41. Hocher B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int 2010; 78:438-45; PMID:20592713; http://dx.doi.org/10.1038/ ki.2010.204.
42. + T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13:6301-11; PMID:17975141; http://dx.doi.org/10.1158/1078-0432.CCR-07-1403.
43. Jackson EK, Ren J, Mi Z. Extracellular 2',3'-cAMP is a source of adenosine. J Biol Chem 2009; 284:33097-106; PMID:19801686; http://dx.doi.org/10.1074/jbc. M109.053876.